Preoperative identification of response to neoadjuvant chemoradiotherapy for esophageal cancer

Preoperative identification of response to neoadjuvant chemoradiotherapy for esophageal cancer - PRIOR

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON39900

Enrollment

Registered

2013-08-06

Start date

2013-10-31

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer oesophageal carcinoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Histologically confirmed carcinoma of the esophagus or esophagogastric junction (i.e. tumors involving both cardia and esophagus on endoscopy) - Potentially resectable tumor (cT1b-4a N0-3 M0) - Undergoing neoadjuvant chemoradiation according to CROSS-regimen - Age >18 years - No history of other cancer or previous radiotherapy or chemotherapy - Signed informed consent

Exclusion criteria

Exclusion criteria: - Patients who meet exclusion criteria for MRI at 1.5T following the protocol of the Radiology department of the UMC Utrecht - Glomerular Filtration Rate (GFR) of

Design outcomes

Primary

Measure	Time frame
- Exploration of the diagnostic value of anatomical and functional MRI and PET-CT in the evaluation of treatment response to nCRT for patients with esophageal cancer, as compared to the pathological specimen as gold standard.	—

Secondary

Measure	Time frame
- Assessment of the optimal (MRI and PET-CT) imaging parameters that correlate best with pathological response. - Assessment of the optimal timing for the imaging series. - Assessment of the diagnostic value of MRI for post-nCRT restaging of T- and N-stage as compared to histopathology. - Assessment of the experienced burden for the patient associated with extra MRI and PET-CT scanning in the clinical work-up for esophageal cancer.	—

Measure

Time frame

- Assessment of the optimal (MRI and PET-CT) imaging parameters that correlate best with pathological response. - Assessment of the optimal timing for the imaging series. - Assessment of the diagnostic value of MRI for post-nCRT restaging of T- and N-stage as compared to histopathology. - Assessment of the experienced burden for the patient associated with extra MRI and PET-CT scanning in the clinical work-up for esophageal cancer.

—

Countries

Netherlands

Outcome results